Canada
Variational AI, founded in 2019, stands at the intersection of AI, Biotechnology, and Machine Learning. Headquartered in Canada, the company has made significant strides in small molecule drug discovery with their flagship product, Enki.
The company’s slogan, "State-of-the-art generative AI for small molecule drug discovery," encapsulates its mission to leverage advanced AI technologies in biopharma. Enki is lauded as the industry's first commercially available foundation model, delivering novel and selective leads to a growing list of biopharma partners and customers.
In terms of financial traction, Variational AI received a $3.50M seed round investment on 17 November 2021, backed by notable investors including Alliance of Angels, Flying Fish Partners, Amarjit Gill, Lip-Bu Tan, and A&E Investments. These endorsements underscore strong investor confidence in the company's pioneering technology and market potential.
